Alam MB,Chowdhury NS,Sohrab MH,Rana MS,Hasan CM,Lee SH .2020 .Cerevisterol alleviates Inflammation via suppression of MAPK/NF-κB/AP-1 and activation of the Nrf2/HO-1 signaling cascade. Biomolecules, 10(2) : 199.
Anstee QM,Castera L,Loomba R .2022 .Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J. Hepatol., 76(6) : 1362-1378.
Cotter TG,Rinella M .2020 .The state of the disease. Gastroenterology, 158(7) : 1851-1864.
Chen CX,Zhang W,Qu S,Xia F,Zhu Y,Chen B Y .2023 .A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways. Cell Commun, 21(1) : 287.
Chen J,Feng S,Li L,Qiu S,Jin Y,Sun Y Y .2022 .Protective role of trametenolic acid B against sevoflurane-induced cognitive impairments by its different regulatory modalities of mir-329-3p in neurons and microglia. Mol. Med, 28(1) : 77.
Duan Q,Tian L,Feng J,Ping X,Li L,Yaigoub H,Li R,Li Y .2022 .Trametenolic acid ameliorates the progression of diabetic nephropathy in db/db mice via Nrf2/HO-1 and NF-κB-mediated pathways. J. Immunol. Res., : 6151847.
Dufour JF,Anstee QM,Bugianesi E,Harrison S,Loomba R,Paradis V,Tilg H,Wong VW,Zelber-Sagi S .2022 .Current therapies and new developments in NASH. , 71(10) : 2123-2134.
Eberhardt J,Santos-Martins D,Tillack AF,Forli S AF .2021 .New docking methods, expanded force field and python bindings. J. Chem, 61(8) : 3891-3898.
Filali-Mouncef Y,Hunter C,Roccio F,Zagkou S,Dupont N,Primard C,Proikas-Cezanne T,Reggiori F .2022 .The ménage à trois of autophagy, lipid droplets and liver disease. Autophagy, 18(1) : 50-72.
Fan L,Niu H,Zhao L,Yao R,He X,Lu B,Pang Z B .2022 .Purendan alleviates non-alcoholic fatty liver disease in aged type 2 diabetic rats via regulating mTOR/S6K1/SREBP-1c signaling pathway. Biomed, 148 : 112697.
Guo X,Yin X,Liu Z,Wang J .2022 .Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and natural products for prevention and treatment. Int. J. Mol. Sci, 23(24) : 15489.
Gong W,Chen X,Shi T,Shao X,An X,Qin J,Chen X,Jiang Q,Guo B .2021 .Network pharmacologybased strategy for the investigation of the antiosteoporosis effects and underlying mechanism of Zhuangguguanjie formulation. Front Pharmacol, 12 : 727808.
Hardesty JE,Wahlang B,Prough RA,Head KZ,Wilkey D,Merchant M,Shi H,Jin J,Cave MC .2021 .Effect of epidermal growth factor treatment and polychlorinated biphenyl exposure in a dietary-exposure mouse model of steatohepatitis. Environ. Health Persp., 129(3) : 37010.
Huang J,Lin Z,Wang Y,Ding X,Zhang B .2023 .Wuling san based on network pharmacology and in vivo evidence against hyperuricemia via improving oxidative stress and inhibiting inflammation. Drug Des. Dev, 17 : 675-690.
Hsieh WT,Hsu MH,Lin WJ,Xiao YC,Lyu PC,Liu YC,Lin WY,Kuo YH,Chung JG,- JG .2021 .-ol Interferes with LPS Docking to LBP, CD14 and TLR4/MD-2 Co-receptors to attenuate the nfκb inflammatory pathway in vitro and drosophila. Int. J. Mol. Sci, 22(12) : 6511.
Huang YP,Chen DR,Lin WJ,Lin YH,Chen JY,Kuo YH,Chung JG,Hsia TC,Hsieh WT,- WT .2021 .-ol attenuates inflammatory responses via inhibiting mapk/ap-1 induced IL-6/JAK/STAT pathways and activating Nrf2/HO-1 signaling in LPS-stimulated macrophage-like cells. Antioxidants, 10(9) : 1430.
Ito Y,Sun R,Yagimuma H,Taki K,Mizoguchi A,Kobayashi T,Sugiyama M,Onoue T,Tsunekawa T,Takagi H,Hagiwara D,Iwama S,Suga H,Konishi H,Kiyama H,Arima H,Banno R H .2022 .Protein tyrosine phosphatase 1b deficiency improves glucose homeostasis in type 1 diabetes treated with leptin. Diabetes., 71(9) : 1902-1914.
Juanola O,Martínez-López S,Francés R,GómezHurtado I .2021 .Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors. Int. J. Environ. Res. Pub. He., 18(10) : 5227.
Johanns M,Corbet C,Jacobs R,Drappier M,Bommer GT,Herinckx G,Vertommen D,Tajeddine N,Young D,Messens J,Feron O,Steinberg GR,Hue L,Rider MH .2022 .Inhibition of basal and glucagon-induced hepatic glucose production by 991 and other pharmacological AMPK activators. Biochem. J., 479(12) : 1317-1336.
Loomba R,Friedman SL,Shulman GI .2021 .Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell., 184(10) : 2537-2564.
Niu B,Xie X,Xiong X,Jiang J .2022 .Network pharmacology-based analysis of the anti-hyperglycemic active ingredients of roselle and experimental validation. Comput. Biol. Med, 141 : 104636.
Portincasa P and Baffy G .2024 .Metabolic dysfunctionassociated steatotic liver disease: Evolution of the final terminology. Eur. J. Intern. Med, 124 : 35-39.
Pansa CC,Molica LR,Moraes KCM .2023 .Nonalcoholic fatty liver disease establishment and progression: genetics and epigenetics as relevant modulators of the pathology. Scand. J. Gastroentero., 58(5) : 521-533.
Pinter M,Pinato DJ,Ramadori P,Heikenwalder M .2023 .NASH and hepatocellular carcinoma: immunology and immunotherapy. Clin. Cancer Res., 29(3) : 513-520.
Pafili K and Roden M .2021 .Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol. Metab, 50 : 101122.
Rong L,Zou J,Ran W,Qi X,Chen Y,Cui H,Guo J .2023 .Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol., 13 : 1087260.
Rinella ME,Neuschwander-Tetri BA,Siddiqui MS,Abdelmalek MF,Caldwell S,Barb D,Kleiner DE,Loomba R .2023 .AASLD Practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. J. Hepatol., 77(5) : 1797-1835.
Shi S,Chen Y,Luo Z,Nie G,Dai Y .2023 .Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy. Cell Commun, 21(1) : 61.
Song Q,Zhang X,Liu W,Wei H,Liang W,Zhou Y,Ding Y,Ji F,Ho-Kwan Cheung A,Wong N,Yu J .2023 .Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J. Hepatol., 79(6) : 1352-1365.
Teng ML,Ng CH,Huang DQ,Chan KE,Tan DJ,Lim WH,Yang JD,Tan E,Muthiah MD .2023 .Global incidence and prevalence of nonalcoholic fatty liver disease. Clin. Mol. Hepatol, 29(Suppl) : S32-S42.
Yan T,Yan N,Wang P,Xia Y,Hao H,Wang G,Gonzalez FJ .2020 .Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta. Pharm. Sin. B., 10(1) : 3-18.
Xu M,Xue H,Kong L,Lin L,Zheng G .2023 .Smilax china L. polyphenols improves insulin resistance and obesity in high-fat diet-induced mice through IRS/AKTAMPK and NF-κB signaling pathways. Plant Food Hum. Nutr, 78(2) : 299-306.
Younossi ZM,Golabi P,Paik JM,Henry A,Van Dongen C and Henry L A .2023 .The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. J. Hepatol., 77(4) : 1335-1347.
Zhang X,Mou Y,Aribas E,Amiri M,Nano J,Bramer WM,Kavousi M,de Knegt RJ,Asllanaj E,Ghanbari M .2022 .Associations of sex steroids and sex hormonebinding globulin with non-alcoholic fatty liver disease: A population-based study and meta-analysis. Genes., 13(6) : 966.
Zhang Y,Murugesan P,Huang K,Cai H K .2020 .NADPH oxidases and oxidase crosstalk in cardiovascular diseases: Novel therapeutic targets. Nature reviews. Cardiology., 17(3) : 170-194.
Zhou Z,Zhang J,You L,Wang T,Wang K,Wang L,Kong X,Gao Y,Sun X Y .2022 .Application of herbs and active ingredients ameliorate non-alcoholic fatty liver disease under the guidance of traditional Chinese medicine. Front Endocrinol., 13 : 1000727.
Zhu K,Guo Y,Zhao C,Kang S,Li J,Wang J,Tang Z,Lin B,Li W .2021 .Etiology exploration of nonalcoholic fatty liver disease from traditional chinese medicine constitution perspective: A cross-sectional study. Front Public Health.,, 9 : 635818.